December Sees Three Milestones For ViiV’s Pipeline
R&D Chief Outlines 2 FDA Filings, 1 Expected Approval
ViiV Healthcare’s R&D head Kimberly Smith tells Scrip December will see the advancement of three key HIV therapies.
You may also be interested in...
ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.